After Altimmune (ALT) reported Q3 results and provided an update focused on its lead program pemvidutide, a GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and metabolic dysfunction-associated steatohepatitis, or MASH, H.C. Wainwright analyst Patrick Trucchio said the firm views the Phase 3 VELOCITY program as being “among the most well-defined and robust in the GLP-1 agonist space.” The firm, which argues that pemvidutide “appears differentiated among GLP-1 compounds,” reiterates a Buy rating and $12 price target on Altimmune shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune Reports Q3 2024 Financial Results and Advances Drug Pipeline
- Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz
- Altimmune Appoints Gregory Weaver as CFO for Growth
- Unusually active option classes on open November 12th
- Altimmune reports Q3 EPS (32c), consensus (35c)